Concepedia

Xue Lin

XL

Statistics

Publications

5

Citations

614

H-Index

5

Active since

2017

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Biologics Evaluation and Research

Xue Lin is an author at United States Food and Drug Administration specializing in cancer therapeutics, cancer research, and tumor immunity.

ORCID

Top concepts

Publications per year

2017–2023

5

Publications

5

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Maura O’Leary, Xiaobin Lü, Ying Huang et al. · Clinical Cancer Research · 2018 · 273 citations · Full text

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Najat Bouchkouj, Yvette L. Kasamon, R. Angelo de Claro et al. · Clinical Cancer Research · 2018 · 220 citations

Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn’s Disease

Juerong Feng, Qiu Xiao, Fan Wang et al. · Gastroenterology Research and Practice · 2017 · 59 citations · Full text

FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Najat Bouchkouj, Xue Lin, Xiaofei Wang et al. · The Oncologist · 2022 · 41 citations · Full text

, , +21

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Poornima Sharma, Yvette L. Kasamon, Xue Lin et al. · Clinical Cancer Research · 2023 · 21 citations · Full text

1–5 of 5